生物治疗中取得的进步在埃索诺菲尔性喘中
Rini Patadia1,2, Thomas B Casale1,2, John Fowler3
1Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA.
Expert opinion on biological therapy
|April 15, 2024
概括
针对关键途径的生物疗法有效地控制了eosinophilic喘. 治疗选择需要考虑患者的表型,并发症和成本效益,以获得最佳的结果.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 喘呈现多种现象,包括2型高 (过敏性,易氨酸性) 和2型低 (非过敏性,往往是中性嗜好性).
- 酸性喘涉及特定的免疫通路 (IgE,IL-4,IL-5,IL-13,TSLP),提供治疗点.
- 气道异性炎症是这种喘亚型的标志,指导治疗策略.
研究的目的:
- 审查当前针对成人酸性喘的生物疗法.
- 讨论临床试验和与生物药物并发症的管理.
- 提供有关选择适合于酸性喘的生物药物的见解.
主要方法:
- 审查当前关于生理疗法的文献对埃索诺菲尔性喘.
- 分析临床试验数据和现实世界的证据.
- 考虑影响生物剂选择的因素.
主要成果:
- 向IgE,IL-4,IL-5,IL-13,TSLP通路的生物药物在酸性喘中表现出有效性.
- 现实世界的研究支持这些向治疗的好处.
- 伴随性疾病往往可以通过同样用于喘的生物药物来解决.
结论:
- 生物疗法为治疗酸性喘提供了显著的好处.
- 个性化治疗选择至关重要,考虑到表型,并发症和成本.
- 进一步的研究可能会完善各种喘群体的生物策略.
关键词:
它们有IL-13和IL-13.IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-4-IL-IL-IL-4-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL-IL is is is is is is what you are is what you are is what you are在IL-5中,IL-5是最常见的.在 IgE 中,IgE 是严重的喘 严重的喘这是TSLP的TSLP.这就是Benralizumab.双重复制的马布.埃奥西诺菲尔是什么意思这就是Mepolizumab.在Omalizumab上使用.这就是Reslizumab.这里是Tzepelumabb的地板.相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
284
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
284
Antiasthma Drugs: Leukotriene Modifiers
282
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
282
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
240
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
240
Drugs Used in Lower Respiratory Disorders: Overview
428
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
428
COPD: Management Using Bronchodilators and Corticosteroids
198
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
198


